CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 10 enrolled
Drug / intervention
Ursolic Acid +1 moredrug
Likely dose
Ursolic Acid 400mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05776862
NCT05776862Phase 2Completed
CompareCT.gov

A Pilot Study Testing Benefits of Ursolic Acid (UA) as a Countermeasure To Myopenia and Insulin Resistance in Chronic Spinal Cord Injury (SCI)

University of Miami·interventional·Posted Mar 20, 2023·Updated May 21, 2025

In Brief

A Phase 2 clinical trial evaluating Ursolic Acid and Strength Training for Spinal Cord Injuries and 5 related conditions. Completed, enrolled 10 participants across 1 site.

Detailed Summary

This study will evaluate if Ursolic Acid supplementation may be effective in reducing muscle loss and improving blood sugar control in the SCI community.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSpinal Cord Injuries, Tetraplegia, Paraplegia, Muscle Loss, Atrophy, Muscular, Insulin Resistance
CountriesUnited States
CollaboratorsFlorida

Timeline

Phase 2CompletedFinished
202420252026
First PostedMar 20, 2023
Enrollment StartMar 27, 2023
Primary CompletionJan 29, 2025
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 3.3 years ago

Interventions

Ursolic Aciddrug

Subjects will take an oral 400mg (8 capsules - 4 in the morning/200mg and 4 at night/200mg) supplement of UA every day for 12 weeks.

Strength Trainingother

Subjects will perform 3 sets of 10 repetitions of concentric and eccentric upper body exercises (bicep curls and tricep extensions) each session. Each session will last approximately 10-15 minutes of weightlifting with a 2-minute rest period between sets. The arm selected for exercise will be randomized.